Mar. 26, 2013, 8:09 PMVenaxis Inc. (APPY) climbs in the post-trade session after providing an update on its clinical and commercial activities, reporting in its 10-K that it continues to enroll patients into its ongoing clinical study of APPY1, and it anticipates completing the study and potentially filing with the FDA for regulatory clearance by year end. Read more on its Business Update Conference Call Here: Business Update Transcript. Shares +5% AH. | Mar. 26, 2013, 8:09 PM | Comment!
APPY vs. ETF Alternatives
Other News & PR